Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Nurix Therapeutics (NRIX) Change in Accured Expenses (2019 - 2025)

Nurix Therapeutics (NRIX) has disclosed Change in Accured Expenses for 7 consecutive years, with $11.0 million as the latest value for Q4 2025.

  • On a quarterly basis, Change in Accured Expenses rose 22.36% to $11.0 million in Q4 2025 year-over-year; TTM through Nov 2025 was $17.3 million, a 46.5% increase, with the full-year FY2025 number at $17.3 million, up 46.5% from a year prior.
  • Change in Accured Expenses was $11.0 million for Q4 2025 at Nurix Therapeutics, up from $6.3 million in the prior quarter.
  • In the past five years, Change in Accured Expenses ranged from a high of $11.0 million in Q4 2025 to a low of -$7.0 million in Q2 2025.
  • A 5-year average of $2.3 million and a median of $3.3 million in 2021 define the central range for Change in Accured Expenses.
  • Peak YoY movement for Change in Accured Expenses: skyrocketed 314.68% in 2022, then crashed 402.88% in 2024.
  • Nurix Therapeutics' Change in Accured Expenses stood at $3.4 million in 2021, then fell by 2.51% to $3.3 million in 2022, then decreased by 6.71% to $3.1 million in 2023, then soared by 193.46% to $9.0 million in 2024, then increased by 22.36% to $11.0 million in 2025.
  • Per Business Quant, the three most recent readings for NRIX's Change in Accured Expenses are $11.0 million (Q4 2025), $6.3 million (Q3 2025), and -$7.0 million (Q2 2025).